Page 5 - B Pfizer News Today

Hospitalizations of U.S. children under 5 with COVID-19 soared in recent weeks to their highest level since the pandemic began, according to government data released Friday on the only age group not yet eligible for the vaccine.

The U.S. is urging that everyone 12 and older get a COVID-19 booster as soon as they're eligible, to help fight back the hugely contagious omicron mutant that's ripping through the country.

The U.S. is urging that everyone 12 and older get a COVID-19 booster as soon as they're eligible, to help fight back the hugely contagious omicron mutant that's ripping through the country.

It is too late for the military; too many in the ranks have been vaccinated ("Pentagon goes to court to defend COVID-19 vaccine mandate for troops," Web, Dec. 27). They are all in a vaccine trial, and Pfizer is apparently not going to tell them or anybody else what to expect for at least 55 years.<

In the debate over drug pricing, many believe that drug-makers spend more on advertising than on research and development, and, consequently, that prices can be cut without damaging innovation.

The Food and Drug Administration on Wednesday authorized for emergency use a pill from drugmaker Pfizer that staved off hospitalization and death from COVID-19 in clinical trials, adding a major tool to the U.S. effort against the virus.

The Food and Drug Administration on Wednesday authorized for emergency use a pill from drugmaker Pfizer that staved off hospitalization and death from COVID-19 in clinical trials, adding a major weapon to the U.S. arsenal against the virus.

COVID-19 vaccines that use messenger RNA are preferable to the Johnson & Johnson vaccine, advisers to the Centers for Disease Control and Prevention said Thursday after reviewing data on an extremely rare but serious blood-clotting disorder linked to the J&J shot.

COVID-19 vaccines that use messenger RNA are preferable to the Johnson & Johnson vaccine, advisers to the Centers for Disease Control and Prevention said Thursday after reviewing data on an extremely rare but serious blood-clotting disorder linked to the J&J shot.

A two-dose Pfizer/BioNTech vaccination provides just 33% protection against infection by the omicron variant of the coronavirus, but 70% protection against hospitalization, according to a large-scale analysis in South Africa released Tuesday.